Total Payments
$9,314
2024 Payments
$4,475
Companies
13
Transactions
31
Medicare Patients
746
Medicare Billing
$171,285
Payment Breakdown by Category
Research$7,172 (77.0%)
Food & Beverage$1,806 (19.4%)
Education$336.57 (3.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,172 | 2 | 77.0% |
| Food and Beverage | $1,806 | 23 | 19.4% |
| Education | $336.57 | 6 | 3.6% |
Payments by Type
Research
$7,172
2 transactions
General
$2,142
29 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $7,172 | 2 | $0 (2024) |
| Amgen Inc. | $520.68 | 6 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $250.30 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $246.82 | 3 | $0 (2021) |
| Genentech USA, Inc. | $235.00 | 2 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $197.21 | 2 | $0 (2018) |
| Lilly USA, LLC | $156.03 | 7 | $0 (2019) |
| PFIZER INC. | $132.19 | 2 | $0 (2023) |
| Janssen Biotech, Inc. | $114.61 | 1 | $0 (2017) |
| BTG International, Inc. | $100.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,475 | 1 | Eli Lilly and Company ($4,475) |
| 2023 | $2,704 | 2 | Eli Lilly and Company ($2,697) |
| 2021 | $15.12 | 1 | E.R. Squibb & Sons, L.L.C. ($15.12) |
| 2019 | $951.85 | 14 | Amgen Inc. ($243.74) |
| 2018 | $685.53 | 7 | Merck Sharp & Dohme Corporation ($250.30) |
| 2017 | $482.65 | 6 | Amgen Inc. ($276.94) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $4,475.00 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 05/23/2023 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $7.20 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $2,696.98 | Research |
| Study: EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 09/20/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $15.12 | General |
| Category: Cardiovascular | ||||||
| 06/19/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $114.32 | General |
| Category: Oncology | ||||||
| 05/17/2019 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: Oncology | ||||||
| 05/16/2019 | PFIZER INC. | TALZENNA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2019 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $77.96 | General |
| Category: Oncology | ||||||
| 05/02/2019 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Oncology | ||||||
| 05/02/2019 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $6.24 | General |
| Category: Oncology | ||||||
| 04/09/2019 | Genentech USA, Inc. | Perjeta (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: BioOncology | ||||||
| 04/03/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $117.38 | General |
| Category: Oncology | ||||||
| 03/27/2019 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 03/23/2019 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Oncology | ||||||
| 03/19/2019 | Amgen Inc. | — | Education | In-kind items and services | $95.00 | General |
| 03/16/2019 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | Cash or cash equivalent | $98.41 | General |
| Category: ONCOLOGY | ||||||
| 03/05/2019 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: Oncology | ||||||
| 03/05/2019 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $1.20 | General |
| Category: Oncology | ||||||
| 12/03/2018 | Takeda Pharmaceuticals U.S.A., Inc. | VELCADE (Drug) | Education | In-kind items and services | $111.24 | General |
| Category: Oncology | ||||||
| 11/15/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2018 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: BioOncology | ||||||
| 09/20/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $85.97 | General |
| Category: Oncology | ||||||
| 09/12/2018 | Lilly USA, LLC | — | Education | In-kind items and services | $28.02 | General |
| 09/06/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $125.31 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2018 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: TOXICITY ANTIDOTE METHOTREXATE TOXICITY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $4,475 | 1 |
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $2,697 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 204 | 383 | $118,566 | $30,109 |
| 2022 | 6 | 219 | 396 | $110,847 | $37,998 |
| 2021 | 6 | 204 | 424 | $115,863 | $51,673 |
| 2020 | 3 | 119 | 417 | $98,262 | $51,505 |
Total Patients
746
Total Services
1,620
Medicare Billing
$171,285
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 293 | $83,357 | $21,134 | 25.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $22,361 | $6,039 | 27.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 20 | 25 | $7,818 | $1,937 | 24.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 17 | 22 | $5,030 | $999.78 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 216 | $57,082 | $15,435 | 27.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 23 | 73 | $11,680 | $11,653 | 99.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 37 | 37 | $18,157 | $4,989 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 35 | $13,440 | $3,784 | 28.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 18 | 20 | $6,817 | $1,548 | 22.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 13 | 15 | $3,671 | $588.59 | 16.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 191 | $61,472 | $20,891 | 34.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 23 | 125 | $20,000 | $20,176 | 100.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 40 | 40 | $18,152 | $5,774 | 31.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 30 | $7,500 | $2,465 | 32.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 18 | 25 | $5,483 | $1,311 | 23.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 13 | $3,256 | $1,058 | 32.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 33 | 191 | $30,560 | $30,253 | 99.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 61 | 201 | $56,988 | $17,911 | 31.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 25 | 25 | $10,714 | $3,341 | 31.2% |
About Dr. Annie Hung, M.D
Dr. Annie Hung, M.D is a Hematology & Oncology healthcare provider based in Gresham, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2013. The National Provider Identifier (NPI) number assigned to this provider is 1730422015.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Annie Hung, M.D has received a total of $9,314 in payments from pharmaceutical and medical device companies, with $4,475 received in 2024. These payments were reported across 31 transactions from 13 companies. The most common payment nature is "" ($7,172).
As a Medicare-enrolled provider, Hung has provided services to 746 Medicare beneficiaries, totaling 1,620 services with total Medicare billing of $171,285. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Gresham, OR
- Active Since 04/04/2013
- Last Updated 06/27/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1730422015
Products in Payments
- KEYTRUDA (Biological) $250.30
- Perjeta (Biological) $125.00
- TALZENNA (Drug) $124.99
- Vectibix (Biological) $124.99
- EMPLICITI (Biological) $117.38
- VERZENIO (Drug) $115.15
- IMBRUVICA (Drug) $114.61
- OPDIVO (Biological) $114.32
- VELCADE (Drug) $111.24
- Avastin (Biological) $110.00
- VORAXAZE (Drug) $100.00
- Nplate (Biological) $98.48
- XGEVA (Biological) $98.47
- VYXEOS (Drug) $98.41
- NINLARO (Drug) $85.97
- Halaven (Drug) $77.34
- Blincyto (Biological) $23.75
- ELIQUIS (Drug) $15.12
- OBIZUR (Biological) $13.76
- CYRAMZA (Drug) $12.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.